Table 4.

Hematological toxicity for cholangiocarcinoma patients receiving either gemcitabine/cisplatin alone (30 patients, referred to as controls) or in combination with silmitasertib (87 patients, referred to as Silmitasertib). The results are presented as the number of patients with the percentage of patients given in parentheses [114].

Toxicity	Anemia		Thrombocytopenia		Neutropenia
	Silmitasertib	Controls	Silmitasertib	Controls	Silmitasertib	Controls
All grades	34 (39%)	9 (30%)	24 (28%)	2 (7%)	27 (31%)	7 (23%)
Grade ≥ 3	17 (20%)	5 (17%)	11 (12%)	1 (3%)	20 (23%)	6 (20%)